A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bepler, G.
Oh, Y.
Burris, H.
Cleverly, A.
Lahn, M.
Herbst, R. S.
机构：
[1] H Lee Moffitt Canc Ctr Res Inst, Tampa, FL USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Sarah Cannon Res Inst, Ashville, TN USA
[4] Eli Lilly & Co, Erlwood, England
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Canakinumab (CAN) plus docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results
    Paz-Ares, L.
    Goto, Y.
    Lim, W. D. T.
    Halmos, B.
    Cho, B. C.
    Dols, M. Cobo
    Gonzalez-Larriba, J. L.
    Zhou, C.
    Demedts, I.
    Atmaca, A.
    Baka, S.
    Mookerjee, B. P.
    Portella, S.
    Zhu, Z.
    Dharan, B.
    Reck, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S953 - S954
  • [32] Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: Efficacy and tolerability
    Camps, C
    Caballero, C
    Blasco, A
    Safont, MJ
    Berrocal, A
    Garde, J
    Juarez, A
    Sirera, R
    Bremnes, RM
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4611 - 4614
  • [33] PHASE II STUDY OF AMRUBICIN FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: UPDATED RESULTS
    Oizumi, Satoshi
    Harada, Toshiyuki
    Ito, Kenichiro
    Takamura, Kei
    Kuda, Tomoya
    Sugawara, Shunichi
    Watanabe, Kana
    Maemondo, Makoto
    Fujita, Yuka
    Kinoshita, Ichiro
    Inoue, Akira
    Hommura, Fumihiro
    Katsuura, Yutaka
    Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    RESPIROLOGY, 2013, 18 : 8 - 8
  • [34] The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options
    Syrigos, Kostas N.
    Saif, Muhammad W.
    Karapanagiotou, Eleni M.
    Oikonomopoulos, George
    De Marinis, Filippo
    ANTICANCER RESEARCH, 2011, 31 (02) : 649 - 659
  • [35] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [36] An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
    Majem, M.
    Pallares, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (05): : 343 - 357
  • [37] An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents
    M. Majem
    C. Pallarès
    Clinical and Translational Oncology, 2013, 15 : 343 - 357
  • [38] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer
    Zietemann, V.
    Duell, T.
    LUNG CANCER, 2011, 73 (01) : 70 - 77
  • [40] Phase II study of dasatinib in non-small cell lung cancer (NSCLC)
    Johnson, F. M.
    Tang, X.
    Tran, H.
    Saigal, B.
    Erasmus, J.
    Kurie, J.
    Hwang, L.
    Oh, Y.
    Lippman, S.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345